Cytosorbents Corporation

CTSO

Net income
-10.4
millions, $
Market cap
256
millions, $
EBITDA
-10.6
millions, $
Revenue
45.1
millions, $
P/E
N/A
Revenue Growth
41
% year on year
Dividends

Estimation

0
% per year
About

CytoSorbents Corp. is involved in the research, development and commercialization of medical devices with its blood purification platform technology. The company focuses on developing this technology for multiple applications in the medical field for the treatment of acute and chronic health complications associated with blood toxicity.

1. There may be a delay in updating the share price

The information on Dastocks.com is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy, or in any other way. Dastocks will not accept liability for any loss or damage, including without limitation any loss of profit, which may arise directly or indirectly from use of or reliance on the information on Dastocks.com. The Authors may buy and sell securities before and after any particular article and/or information herein is published.

You must accept the terms and conditions if you wish to continue to use the Dastocks website.